The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx
Trends of survival based on race and ethnicity in gastrointestinal tract neuroendocrine tumor.
 
Suleyman Yasin Goksu
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Ipsen; Ipsen; Ipsen; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
 
Nina Niu Sanford
No Relationships to Disclose
 
Benjamin David Fangman
No Relationships to Disclose
 
Sarah Herrman
No Relationships to Disclose
 
Busra Bacik Goksu
No Relationships to Disclose
 
Udit Verma
No Relationships to Disclose
 
Aravind Sanjeevaiah
Travel, Accommodations, Expenses - NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier
 
Amy Little Jones
No Relationships to Disclose
 
Radhika Kainthla
No Relationships to Disclose
 
Syed Mohammad Ali Kazmi
No Relationships to Disclose